Natural vs Chemicals: Why Natural Doesn’t Always Mean Safe

Executive summary

Table of contents

• The appeal-to-nature fallacy
• Natural but dangerous
• Manufactured and processed: context matters
• The dose makes the poison
• How safety is actually determined
• Practical guidance
• Sources and funding notes

The appeal-to-nature fallacy

The claim "natural equals safe, chemical equals dangerous" is a textbook example of the appeal-to-nature fallacy: the mistaken belief that because something occurs in nature it must be good or harmless. It collapses on two basic facts.

Chemical identity alone does not establish risk. Water and sodium chloride are chemicals, and caffeine has the same molecular identity whether extracted from a plant or synthesized. Products can still differ in purity, dose and accompanying ingredients; a chemical-free claim does not describe an ordinary physical product. Grandjean 2014 review; EFSA caffeine guidance.

Paracelsus wrote his dose principle in 1538; it was published in 1564. Modern toxicology also considers timing, susceptibility and uncertainty in exposure measurement. Intake guidance values and study effect levels help assess risk, but not every regulatory classification is a dose threshold or a guarantee of zero risk. Grandjean 2014 review; IARC classification Q&A.

Natural but dangerous

The examples below illustrate different hazards: acute poisoning, organ injury and cancer. Their different routes, preparations and evidence bases do not support a common potency ranking. CDC botulism guidelines; IARC aflatoxin evaluation; ATSDR mercury profile.

Botulinum toxin — an exceptionally potent biological toxin

Botulinum neurotoxin is a protein produced by the bacterium Clostridium botulinum — entirely natural, no synthesis required.

• Human lethal doses are estimates, not measured safety thresholds. CDC gives estimates for purified type A toxin in a 70 kg adult of about 70 µg orally and 0.80–0.90 µg inhaled; the precise human dose is unknown and varies by route (CDC botulism guidelines).
• Botulism can be fatal, and outcomes differ by type of illness, patient population, care and reporting period. Historical case-fatality figures are not a fixed probability for every exposure or a dose threshold. StatPearls botulism chapter; CDC botulism guidelines.
• Horowitz’s 2005 review describes botulinum toxin’s exceptional potency. Its historical dose estimates are route-dependent and should not be interpreted as measured human safety boundaries. Horowitz 2005 review.

Purified botulinum toxins also have controlled medical uses, while excessive or inappropriate therapeutic exposure can cause iatrogenic botulism. Formulation, route and clinical supervision matter alongside dose. CDC botulism guidelines.

Ricin — natural, weaponized, lethal

Ricin is a ribosome-inactivating protein from the castor bean (Ricinus communis), the same plant grown to produce castor oil.

• Ricin toxicity depends strongly on whether exposure occurs by ingestion, inhalation or injection. Published lethal-dose estimates are not measured personal boundaries, and castor-seed toxicity varies with the material and preparation. StatPearls ricin chapter; CDC ricin guidance.
• Chewing castor seeds can release ricin. Its inhibition of protein synthesis explains the cellular mechanism, but laboratory potency does not directly quantify a human clinical dose. StatPearls ricin chapter; CDC ricin guidance.
• CDC describes ricin as a poison found in castor beans and documents its use in the 1978 assassination of Georgi Markov. Suspected exposure requires urgent professional assessment; the historical example is not a dose guide. CDC ricin guidance.

Aflatoxin — natural mold toxin, IARC Group 1 liver carcinogen

Aflatoxins are fungal contaminants that can occur in foods such as maize and peanuts. IARC classifies naturally occurring aflatoxins as carcinogenic to humans, with sufficient evidence for liver cancer. Natural origin does not protect against this hazard, and it is unrelated to a food’s organic certification. IARC aflatoxin evaluation.

Death cap mushroom (Amanita phalloides) — natural, causes fatal liver failure

• The 2012 Amanita review reports historical estimates that amatoxins accounted for about 90% of mushroom-poisoning deaths and 50–100 annual fatal cases in Western Europe. These are the review’s estimates, not a current surveillance census or the risk from any individual mushroom exposure. Amanita 2012 review.
• The review cites an estimated fatal amatoxin amount and notes that a single mushroom may contain a dangerous quantity. Mushroom size, toxin content and clinical circumstances vary; there is no reliable personal safe-dose calculation. Amanita 2012 review.
• The review describes a symptom-free interval of roughly 6–40 hours before gastrointestinal symptoms. Liver injury and failure can develop later. Its cited 10–20% mortality range reflects reported clinical experience, with outcomes depending on treatment and case selection. Amanita 2012 review.

Cyanide in apricot kernels and laetrile — natural, active poisoning cases, FDA warnings

Amygdalin — marketed as "laetrile" or "vitamin B17" — is a natural compound in apricot kernels that releases hydrogen cyanide when metabolized.

• In a published case, a 73-year-old man with metastatic pancreatic cancer developed severe lactic acidosis after taking three 500 mg amygdalin tablets. The report calculated a potential cyanide yield of 90 mg; it did not assay that yield or establish a universal human lethal threshold. Amygdalin case report.
• Oral amygdalin can release cyanide, with toxicity affected by metabolism and accompanying foods. NCI’s reference PDQ review finds that clinical reports have not established laetrile as an effective cancer treatment; it is not FDA-approved for cancer treatment. Amygdalin case report; NCI laetrile review.
• FDA’s May 24, 2024 alert concerned three named Apricot Power Bitter Apricot Seeds lots with elevated amygdalin. The firm had declined the requested recall. This lot-specific alert does not establish the contents of every apricot-seed product. FDA apricot-seed alert.

Comfrey and pyrrolizidine alkaloids — oral-use liver-injury concerns

Comfrey (Symphytum) contains hepatotoxic pyrrolizidine alkaloids.

• Comfrey is rated a "probable cause" (likelihood score C) of clinically apparent liver injury — specifically hepatic sinusoidal obstruction syndrome — typically within 1–2 months of oral use (Comfrey, LiverTox/NCBI).
• One historical analysis found 26 mg of pyrrolizidine alkaloids in a cup of comfrey tea; amounts vary. Oral comfrey has caused severe or fatal liver injury, while some infant cases in the bibliography involved other pyrrolizidine-containing plants (LiverTox/NCBI).
• LiverTox documents an FDA warning in 2001 about comfrey-related liver injury. This historical reference does not establish every country’s current law or the safety of every oral or topical preparation. LiverTox comfrey.

Ephedrine-alkaloid supplements — FDA ban effective in 2004

• FDA published its final rule on February 11, 2004, effective April 12, 2004, prohibiting dietary supplements containing ephedrine alkaloids because they presented an unreasonable risk. Its assessment considered pharmacology, published literature and adverse-event reports. FDA ephedrine-alkaloid rule.
• Harvard’s 2004 consumer overview discusses historical supplement sales and poison-centre reports. Such reporting comparisons cannot establish a causal adverse-event incidence or the relative risk for an individual user. Harvard 2004 overview; FDA ephedrine-alkaloid rule.

Kava — natural, well-established hepatotoxicity

Kava (Piper methysticum) is a Pacific botanical traditionally used for anxiety.

• Kava has a LiverTox likelihood score of "A" — a well-known cause of clinically apparent liver injury, including cases requiring liver transplantation and cases ending in death (Kava Kava, LiverTox/NCBI).
• LiverTox summarizes severe liver-injury cases, including a patient taking a kava product supplying 240 mg/day kavalactones who required transplantation, and another taking a combination herbal product who died after transplantation. Case reports cannot establish a universal dose cutoff or isolate every formulation’s causal contribution. LiverTox kava.
• LiverTox describes historical safety warnings and restrictions in several countries. Its 2018 chapter does not establish every country's current rules or a universal safe kava dose (LiverTox/NCBI).

Aristolochic acid — natural, causes kidney failure and urinary-tract cancer

Aristolochic acids occur naturally in Aristolochia herbs used in some traditional remedies.

• A Belgian outbreak involved at least 100 patients, mostly middle-aged women on a weight-loss regimen, who developed rapidly progressive renal fibrosis known as "Chinese herb nephropathy." Among 39 who had prophylactic surgery, 18 harbored urothelial cancers (Aristolochia species and aristolochic acids, IARC Vol. 82).
• The 2002 IARC evaluation classified Aristolochia-containing herbal remedies as Group 1, while aristolochic acid itself was then Group 2A. The later classification list identifies aristolochic acid and plants containing it as Group 1, with the 2012 Volume 100A evaluation. IARC 2002 evaluation; IARC classification list.

Lead, arsenic and mercury — chemical form and exposure matter

Naturally occurring metals can cause serious harm. WHO describes lead’s effects on children’s brain development and the cancer risk from long-term inorganic arsenic exposure; ATSDR distinguishes elemental, inorganic and organic mercury because their routes and effects differ. WHO lead guidance; WHO arsenic guidance; ATSDR mercury profile.

• Grandjean’s review describes an association of about six IQ points per doubled prenatal methylmercury exposure in a genetically susceptible subgroup of a British birth cohort. This subgroup result is not a universal causal estimate for all mercury exposure or a model of generic poisoning incidents. Grandjean 2014 review.
• Arsenic and inorganic arsenic compounds are IARC Group 1 carcinogens. This classification is separate from mercury’s classifications and is supported by IARC’s own list. Natural occurrence does not determine safety; chemical form, route and exposure still matter. IARC classification list; WHO arsenic guidance.

Tobacco exposure — a plant-derived source of preventable harm

Smoking and secondhand smoke cause almost nine in ten lung-cancer deaths, according to CDC. The agency identifies about 742,000 US cancer diagnoses in 2022 of types associated with tobacco; it does not attribute every one to tobacco. Plant origin does not protect against tobacco exposure, and processing or combustion also matters. CDC tobacco guidance.

Manufactured and processed: context matters

Manufactured medicines, supplements and treated drinking water can provide benefits under defined conditions. Their evidence, standards and oversight differ by product category; industrial production does not itself prove that a product was rigorously tested or is safe for every person. FDA supplement guidance; FDA GRAS guidance; EPA drinking-water standards.

Creatine monohydrate — synthetically manufactured, among the most-studied supplements, with safety evidence under tested conditions

Creatine is present in the body and is supplied in commercial supplements, most commonly as creatine monohydrate. The evidence concerns the tested ingredient, formulation and exposure; it does not establish every manufacturer’s purity or every product’s equivalence. ISSN 2017 position stand; Kreider 2025 analysis.

• The 2025 analysis included 685 creatine study groups and 652 placebo groups, with 12,839 and 13,452 participants respectively. Overall participant-level differences were not significant, while some study-level gastrointestinal and cramping comparisons differed. Mean duration across both study-group sets was about 65 days; the longest reported studies do not establish universal long-term safety. Missing mentions of listed side effects were coded as zero. Kreider 2025 analysis.
• The 2017 ISSN position stand describes a generally favourable creatine-monohydrate safety profile in studied healthy and clinical populations. Its broad dose-duration summary is not a recommendation that everyone can take 30 g/day for five years. The manuscript received Council for Responsible Nutrition support, and several authors disclosed commercial relationships. ISSN 2017 position stand.

Caffeine — exposure and individual context matter

• EFSA reports no safety concerns for single caffeine doses up to 200 mg and habitual intakes up to 400 mg/day in healthy adults. Its guidance uses 200 mg/day during pregnancy and lactation, considers all dietary sources, and notes that 100 mg near bedtime can affect sleep. Disease and medicine-combination assessments are outside this guidance’s scope. EFSA caffeine guidance.
• EFSA’s examples are approximately 90 mg caffeine in 200 mL filter coffee and 80 mg in a 60 mL espresso. Actual servings vary. Molecular identity does not eliminate dose, formulation, sleep, interaction or susceptibility concerns, and this guidance does not establish a personal lethal-dose estimate. EFSA caffeine guidance.

Fluoridation — a recommendation with a defined purpose

The US community-water recommendation is 0.7 mg/L fluoride to prevent tooth decay while minimizing dental fluorosis. NIDCR distinguishes this level from studies of substantially higher exposure; those studies do not establish an IQ effect at 0.7 mg/L. This is an oral-health recommendation, not a guarantee of zero risk at every exposure or in every setting. CDC fluoridation recommendation; NIDCR fluoridation guidance.

Chlorine — a water-treatment chemical that saves lives

Chlorine and chloramine help control disease-causing organisms in drinking water. EPA’s 4 mg/L maximum residual disinfectant level for each is a public-water-system standard, not a dose target or a guarantee about every byproduct. CDC separately discusses disinfection byproducts, corrosion and the need to remove disinfectants from dialysis water. CDC water-disinfection guidance; EPA drinking-water standards.

Manufactured insulin and metformin — different diabetes treatments

Most people with type 1 diabetes need insulin to stay alive. The metformin review describes a synthesized medicine used principally for type 2 diabetes; it is a narrative biological/chemical overview, not a new comparative efficacy trial. Medicines require appropriate selection, dosing and monitoring. NIDDK type 1 diabetes guidance; Metformin 2023 overview.

The dose makes the poison

An essential substance can be harmful in excessive exposure, while a manufactured product can be useful under appropriate conditions. Dose is one determinant of risk alongside route, duration, timing, formulation and individual vulnerability. Neither natural nor synthetic origin substitutes for evidence about the actual use. Grandjean 2014 review; Salt-fatalities systematic review; Five-child iron case series.

Water, sodium, iron and vitamins A and D are essential; caffeine is a nonessential stimulant. All can cause harm in excessive exposure. Risk depends on dose, exposure route, duration and individual susceptibility, and a regulatory limit does not guarantee zero risk for every person (Salt fatalities review, PMC; EFSA).

How safety is actually determined

Safety oversight follows product category and intended use. FDA does not preapprove dietary supplements for safety and effectiveness, whether their ingredients are natural or manufactured. Medicines, food additives and GRAS food uses follow different pathways, and compliant status alone is not a zero-risk guarantee. FDA supplement guidance; FDA GRAS guidance.

• NOAEL and ADI are different measures. A NOAEL is a no-adverse-effect level observed in a particular study; an ADI is a guidance value for repeated intake. For example, JECFA used a rat NOAEL and a 100-fold uncertainty factor for Brilliant Blue FCF. Other assessments can use different evidence, starting points or factors; an ADI is not a personal boundary. JECFA Brilliant Blue evaluation.
• FDA GRAS concerns a substance’s intended food use and recognition of safety by qualified experts. It provides an exception from food-additive premarket approval through scientific procedures or, for older uses, common-use evidence. GRAS is not FDA premarket approval of every product containing that substance. FDA GRAS guidance.
• EFSA publishes scientific assessments, including its caffeine guidance. The conclusions concern the specified population, exposure and evidence; agency authorship does not establish that every underlying study was free of commercial interests. EFSA caffeine guidance.
• IARC groups describe the strength of evidence for a cancer hazard: 1, carcinogenic; 2A, probably carcinogenic; 2B, possibly carcinogenic; and 3, not classifiable. They do not rank potency or predict risk at a specific exposure, and Group 3 does not mean safe. The system does not assign safety from an agent’s natural or manufactured origin. IARC classification Q&A.
• JECFA evaluates particular food-additive exposures, as its Brilliant Blue ADI illustrates. Poison-centre and adverse-event reports can identify possible harms, but reported exposure is not necessarily verified poisoning or proven causation, and such systems do not capture every event. JECFA Brilliant Blue evaluation; FDA supplement guidance; Original vitamin D exposure paper.

Practical guidance

1. Assess the actual ingredient, preparation and exposure. Consider dose, route, duration, quality, interactions and vulnerability, alongside human evidence and the applicable regulatory guidance. A natural or chemical label does not answer these questions. Grandjean 2014 review; FDA supplement guidance.
2. Follow age- and use-specific guidance where it applies. ADIs, tolerable upper intake levels and clinical dosing rules are different; not every substance has an ADI. Poisoning reports must not be used to calculate a personal safe dose, and suspected overdose needs prompt professional assessment. StatPearls water-toxicity chapter; NIH ODS vitamin A; StatPearls vitamin D chapter; Salt-fatalities systematic review.
3. Avoid using apricot kernels or laetrile as cancer treatment, oral comfrey products, prohibited ephedrine-alkaloid supplements or Aristolochia-containing remedies. Kava products have also been linked to severe liver injury; a claimed natural origin or dose does not establish safety. Product-specific medical advice matters. FDA apricot-seed alert; NCI laetrile review; LiverTox comfrey; FDA ephedrine-alkaloid rule; LiverTox kava; IARC classification list.
4. Check the exact product’s current certification listing and the programme’s scope. NSF describes label-content, contaminant and toxicology checks with audits and periodic retesting. This is a certification service, not evidence of clinical benefit, a guarantee about every lot or assurance of suitability for every person. NSF certification guide.
5. A 2020 study sampled 277 dietary supplements marketed in the UAE. Three products exceeded the study’s AHPA-derived daily-exposure benchmarks for cadmium or lead; none exceeded its arsenic benchmark. This selected-market sample and benchmark do not establish all-market prevalence, universal safe levels or the purity of every product. UAE supplement survey.

Origin alone cannot establish safety. Naturally occurring toxins and contaminants can cause serious harm, while medicines, supplements and treated water can be useful in defined settings. Their formulations, evidence quality, oversight and risks differ. Identify the actual exposure, account for susceptibility and uncertainty, and follow relevant clinical and regulatory guidance. Grandjean 2014 review; CDC botulism guidelines; Kreider 2025 analysis; FDA supplement guidance; EPA drinking-water standards.

Sources and funding notes

• Botulism: CDC’s clinical guideline distinguishes routes, toxin preparations and clinical care. Its authors reported no related manufacturer/service financial interests, while two technical experts had reviewed conflicts; the evidence set includes unpublished manufacturer allergy trials. StatPearls and Horowitz are secondary clinical reviews, and complete Horowitz funding/disclosures were not recovered. CDC botulism guidelines; StatPearls botulism chapter; Horowitz 2005 review.
• Ricin: StatPearls provides clinical review context and CDC public-health guidance. Neither source is an original exposure experiment establishing an individual lethal threshold. The complete clinical chapter and its full financial disclosures were not recovered. StatPearls ricin chapter; CDC ricin guidance.
• Aflatoxin: IARC’s evaluation supports the human liver-cancer hazard classification. It is a working-group synthesis of human, animal and mechanistic evidence; the finances of every underlying study are not established here. IARC aflatoxin evaluation.
• Death cap: the full 2012 narrative review supplies clinical phases and historical estimates. No separate funding or conflict declaration was located in that main paper; its referenced case finances and current surveillance burden remain separate questions. Amanita 2012 review.
• Amygdalin: the full case report declares no conflicts but does not separately report study funding; its 90 mg cyanide figure is calculated. FDA’s alert is lot-specific regulatory evidence. NCI’s reference PDQ review addresses treatment evidence; it is not a newly conducted efficacy trial. Amygdalin case report; FDA apricot-seed alert; NCI laetrile review.
• Comfrey: LiverTox’s clinical synthesis supports oral pyrrolizidine-alkaloid injury concerns and identifies probable causation. The full texts and finances of every cited case were not recovered, and the chapter is not a current global legal survey. LiverTox comfrey.
• Ephedra: FDA’s operative rule establishes the US ephedrine-alkaloid supplement prohibition and effective date. Harvard’s 2004 article provides historical consumer context; its absence of a product-funding statement is not proof of no product funding or proof that every reported event was causal. FDA ephedrine-alkaloid rule; Harvard 2004 overview.
• Kava: LiverTox summarizes severe liver-injury cases and causality limitations, including combination products. Complete original case reports and their financial relationships were not all recovered; case doses cannot establish a universal safe boundary. LiverTox kava.
• Aristolochic acid: the 2002 IARC evaluation and later classification list have different roles. IARC’s 2022 news item summarizes a review; it does not substitute for the original classification decision or disclose all underlying study finances. IARC 2002 evaluation; IARC classification list; IARC review summary.
• Metals: WHO’s lead and arsenic fact sheets provide public-health guidance. ATSDR’s October 2024 mercury profile distinguishes chemical forms, routes and evidence; its contributors include ATSDR and SRC, with governmental and external reviewers. These documents do not establish the finances of every cited underlying study. WHO lead guidance; WHO arsenic guidance; ATSDR mercury profile.
• Tobacco: CDC’s current public-health page supports the smoking/secondhand-smoke lung-cancer burden statement. Its count of diagnoses of tobacco-associated cancer types is not a count of tobacco-attributable diagnoses or an original causal analysis conducted for this article. CDC tobacco guidance.
• Creatine: AlzChem paid the 2025 paper’s publication charges; Kreider and Bonilla disclosed AlzChem advisory roles and other industry relationships. The 2017 ISSN manuscript received Council for Responsible Nutrition support, with several authors reporting supplement-company roles or commercial activities. These declarations do not identify the financing and procurement terms of every constituent trial. Kreider 2025 analysis; ISSN 2017 position stand.
• Caffeine: EFSA’s guidance applies to the specified healthy populations and all-source exposure. Its clinical scope excludes disease and medication-combination assessments; the overview does not independently clear each underlying study’s financial interests. EFSA caffeine guidance.
• Fluoride: CDC and NIDCR explain the oral-health recommendation and distinguish higher-exposure research. The primary guidance was read; a complete new review of every underlying trial, NTP method and financial relationship is not established here. CDC fluoridation recommendation; NIDCR fluoridation guidance.
• Chlorine/chloramine: CDC addresses disinfection, byproducts, corrosion and dialysis, while EPA provides enforceable public-water-system standards. Regulatory concentration limits are not individual treatment recommendations or a claim that every underlying toxicology study is financially independent. CDC water-disinfection guidance; EPA drinking-water standards.
• Insulin: NIDDK guidance supports its necessity for most type 1 patients. The 2023 metformin narrative overview reports CONACyT grants FORDECYT-PRONACES/610286/2020 and FIDCC 2022/321616, a fellowship and no known competing interests. Its abstract and indexed original synthesis/disclosure sections were recovered; the complete paper and the finances of its cited efficacy studies were not. NIDDK type 1 diabetes guidance; Metformin 2023 overview.
• Water toxicity: original indexed clinical sections describe hyponatremia and the separate danger of overly rapid correction. Complete chapter delivery and disclosures were not recovered; the clinical text is not an individual intake or treatment prescription. StatPearls water-toxicity chapter.
• Salt: the review collected 35 deaths from 27 reports, with estimated amounts and important case-selection/co-ingestion limitations. Campbell disclosed paid Novartis Foundation hypertension-programme work and Midway blood-pressure-device consultation, alongside unpaid WASH membership. Train declared no funding/conflicts and described unpaid Open Arms work; private agreement terms remain unknown. Salt-fatalities systematic review.
• Iron: the complete five-child retrospective PICU series and case tables report two deaths after estimated 200 and 50 mg/kg ingestions. The authors declare nil financial support and no conflicts; dose estimation and selected cases still limit prediction, and unreported care/procurement details remain unknown. Five-child iron case series.
• Vitamin A: NIH ODS provides preformed-A intake limits and excessive-intake context; StatPearls supplies clinical review material. Full ODS relevant guidance and selected indexed clinical sections were read, but complete clinical-chapter disclosures and finances of every underlying study were not recovered. NIH ODS vitamin A; StatPearls vitamin A chapter.
• Vitamin D: the complete NPDS original paper declares no financial support for research, authorship or publication and no potential conflicts. Its self-reported exposure records are not verified poisoning incidence; absent calcium/25(OH)D data and short follow-up limit inference. StatPearls supplies separate partial clinical context. Original vitamin D exposure paper; Vitamin D exposure study; StatPearls vitamin D chapter.
• Dose concept: Grandjean’s full academic review reports NIEHS grants ES009797, ES012199 and ES021477 and no conflicts. It discusses timing, genetic susceptibility and measurement uncertainty; a British susceptible-subgroup association cannot be generalized to all mercury exposures. The finances of every cited original cohort remain separate. Grandjean 2014 review.
• GRAS and supplement oversight: FDA guidance establishes the intended-use and product-category framework. A notifier’s safety determination, FDA oversight and each underlying study’s financial interests are different questions; a GRAS claim is not automatic FDA premarket approval. FDA GRAS guidance; FDA supplement guidance.
• IARC: the original Q&A defines the four hazard-evidence groups and distinguishes them from exposure-specific risk. The classification list identifies particular agents and evaluations; these are official programme records, not a financial clearance of every working group or referenced study. IARC classification Q&A; IARC classification list.
• UAE supplement survey: the full 2020 paper measured 277 selected products and declares no conflicts. No separate study-funding statement was located. Its AHPA-derived exposure benchmarks, sampling frame and recommended-label-dose calculations do not establish all-market safety, every supplier’s purity or an independently cleared procurement chain. UAE supplement survey.
• NSF: its certification guide describes a service for product-content, contaminant and toxicology review, audits and periodic retesting. NSF’s seller FAQ lists fees for testing and product certification; exact product listing, provider relationships and clinical efficacy are different questions. The guide does not establish every-lot testing or each client’s private terms. NSF certification guide; NSF service-fee FAQ.

Clinical studies, case reports, surveillance, laboratory findings and official guidance have different roles. Their limitations and reported financial relationships should be assessed separately; an unreported or inaccessible funding detail remains unknown rather than clear. These examples support judging actual exposures, not assigning safety from origin. Grandjean 2014 review; Kreider 2025 analysis; Salt-fatalities systematic review; FDA supplement guidance.